We rank companies based on fund manager, research analyst and news sentiment
ALGS stock icon

Aligos Therapeutics


About: Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Employees: 66

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

57% more capital invested

Capital invested by funds: $19.2M [Q3] → $30.1M (+$10.9M) [Q4]

11% more funds holding

Funds holding: 36 [Q3] → 40 (+4) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

0.56% less ownership

Funds ownership: 63.68% [Q3] → 63.13% (-0.56%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ALGS.

Financial journalist opinion